Akari Therapeutics (AKTX) Expected to Announce Quarterly Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) will likely be posting its Q4 2025 results after the market closes on Tuesday, April 7th. Analysts expect the company to announce earnings of ($0.0450) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last issued its earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter.

Akari Therapeutics Price Performance

Shares of AKTX opened at $0.12 on Tuesday. Akari Therapeutics has a 52-week low of $0.12 and a 52-week high of $1.58. The business’s 50 day moving average price is $0.23 and its two-hundred day moving average price is $0.45.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Akari Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $1.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $2.53.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics as of its most recent SEC filing. 5.06% of the stock is currently owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.